Rather than a one-size-fits-all blood test that looks for a single pathology, NeuroDex is commercializing a novel scientific approach, based on the study of extracellular vesicles – that can decipher “mixed pathology” in dementia and lead to a more personalized treatment plan. The Challenge Whenever we write about a company in the Alzheimer’s Moonshot we…
We are thrilled to announce that Dr. Erez Eitan, NeuroDex’s chief scientific officer (CSO), will participate in the upcoming Alzheimer’s Association International Conference (AAIC) 2024. This prestigious event, taking place from July 28 to August 1 in Philadelphia, USA, will bring together leading scientists, researchers, and healthcare professionals from around the globe to discuss the…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
In a groundbreaking move poised to reshape the landscape of brain disease treatments, CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) has announced the successful completion of its merger with EIP Pharma Inc. This milestone marks the birth of a dynamic clinical-stage biotechnology company committed to advancing innovative therapies for degenerative diseases. The company’s press…
Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…
Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…
Neurodegenerative diseases Neurodegenerative diseases are a complex and growing public health concern. These conditions, including Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, can cause significant disability and reduced quality of life. Unfortunately, diagnosing these diseases can be challenging, with current diagnostic methods often requiring invasive procedures, such as brain imaging or lumbar puncture. Neurodex…